文献速递帕金森病与运动障碍

帕金森病冲动控制障碍的纵向分析

Longitudinal analysis of impulse control disorders in Parkinson disease.
PubMed 文献 · Neurology · 2018-06-20

这项多中心纵向队列研究纳入411例病程≤5年的帕金森病患者,每年面对面评估冲动控制障碍(ICDs),中位随访3.3年。基线无ICDs的306例患者5年累积发病率为46.1%,ICDs与多巴胺受体激动剂使用相关(患病率比4.23),且呈剂量效应关系,停药后ICDs逐渐缓解。

要点

  • 基线无ICDs患者5年累积发病率为46.1%,多巴胺受体激动剂使用者为51.5%,从未使用者为12.4%。
  • ICDs与曾使用多巴胺受体激动剂相关,患病率比4.23(95%CI 1.78-10.09)。
  • 多巴胺受体激动剂的疗程和日剂量均与ICDs独立相关,呈剂量效应关系;停药后ICDs逐渐缓解。

核心结论

  • 在这项多巴胺受体激动剂治疗比例较高的帕金森病纵向研究中,ICDs的5年累积发病率约为46%。
  • ICDs与多巴胺受体激动剂使用强相关且呈剂量效应关系,疗程延长和剂量增加均与ICDs相关。
  • 停用多巴胺受体激动剂后ICDs逐渐缓解。

研究设计与样本

  • 多中心纵向队列,连续纳入基线病程≤5年的帕金森病患者,每年随访至5年。
  • ICDs由运动障碍专科医生通过面对面半结构化访谈评估。
  • 采用广义估计方程和稳健方差的泊松模型分析不同时间依赖定义的多巴胺受体激动剂使用(考虑剂量和疗程)与每次访视时ICDs的关联,并检查其他抗帕金森病药物。
  • 共纳入411例患者(女性40.6%,平均年龄62.3岁,平均随访3.3年,SD 1.7年),其中356例(86.6%)自起病以来至少使用过一次多巴胺受体激动剂。
  • 基线无ICDs的306例患者纳入5年累积发病率分析。

主要发现

  • 基线无ICDs的306例患者5年累积ICDs发病率为46.1%(95%CI 37.4-55.7),曾使用多巴胺受体激动剂者为51.5%(95%CI 41.8-62.1),从未使用者为12.4%(95%CI 4.8-30.0)。
  • ICDs患病率从基线的19.7%上升至5年后的32.8%。
  • ICDs与曾使用多巴胺受体激动剂相关,患病率比4.23(95%CI 1.78-10.09)。
  • 多巴胺受体激动剂的终生平均日剂量和疗程均与ICDs独立相关,呈显著剂量效应关系。
  • 对左旋多巴的类似分析不支持强关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the longitudinal dose-effect relationship between dopamine replacement therapy and impulse control disorders (ICDs) in Parkinson disease (PD). METHODS: We used data from a multicenter longitudinal cohort of consecutive patients with PD with ≤5 years' disease duration at baseline followed up annually up to 5 years. ICDs were evaluated during face-to-face semistructured interviews with movement disorder specialists. Generalized estimating equations and Poisson models with robust variance were used to study the association between several time-dependent definitions of dopamine agonist (DA) use, taking dose and duration of treatment into account, and ICDs at each visit. Other antiparkinsonian drugs were also examined. RESULTS: Among 411 patients (40.6% women, mean age 62.3 years, average follow-up 3.3 years, SD 1.7 years), 356 (86.6%) took a DA at least once since disease onset. In 306 patients without ICDs at baseline, the 5-year cumulative incidence of ICDs was 46.1% (95% confidence interval [CI] 37.4-55.7, DA ever users 51.5% [95% CI 41.8-62.1], DA never users 12.4% [95% CI 4.8-30.0]). ICD prevalence increased from 19.7% at baseline to 32.8% after 5 years. ICDs were associated with ever DA use (prevalence ratio 4.23, 95% CI 1.78-10.09). Lifetime average daily dose and duration of treatment were independently associated with ICDs with significant dose-effect relationships. Similar analyses for levodopa were not in favor of a strong association. ICDs progressively resolved after DA discontinuation. CONCLUSION: In this longitudinal study of patients with PD characterized by a high prevalence of DA treatment, the 5-year cumulative incidence of ICDs was ≈46%. ICDs were strongly associated with DA use with a dose-effect relationship; both increasing duration and dose were associated with ICDs. ICDs progressively resolved after DA discontinuation. CLINICALTRIALSGOV IDENTIFIER: NCT01564992.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018. PMID: 29925549. doi:10.1212/WNL.0000000000005816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。